Oragenics Inc.
Oragenics Inc. does not currently have a price target or an analyst rating. However, the company has been working on a number of different projects.
These have contributed to a buildup of momentum in the fourth quarter. In fact, since November 20th, OGEN stock has risen from around $0.38 to highs of $0.6499 this week.
That's a gain of more than 70% in just a few weeks, resulting from a move of less than 30 cents. The company recently completed a $6 million public offering, which provides the capital required to expand on its preclinical developments.
Oragenics is specifically working on a SARS-CoV-2 vaccine, Terra CoV-2, as well as its lantibiotics program.
Oragenics is specifically working on a SARS-CoV-2 vaccine, Terra CoV-2, as well as its lantibiotics program.
Website: www.oragenics.com
Market Cap: 47.769M
